Geovax Labs für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1CWWR / ISIN: US3736782000

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Geovax Labs Inc

20.10.25		EQS-News: GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases (EQS Group)
16.10.25		EQS-News: GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025 (EQS Group)
13.10.25		EQS-News: GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions (EQS Group)
09.10.25		EQS-News: GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025 (EQS Group)
07.10.25		EQS-News: GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (EQS Group)
01.10.25		EQS-News: GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit (EQS Group)
30.09.25		EQS-News: GeoVax Labs Announces $2.5 Million Registered Direct Offering (EQS Group)
29.09.25		EQS-News: GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security (EQS Group)
24.09.25		EQS-News: GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications (EQS Group)
22.09.25		EQS-News: GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations (EQS Group)
18.09.25		EQS-News: GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference (EQS Group)
15.09.25		EQS-News: GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference (EQS Group)
12.09.25		EQS-News: GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference (EQS Group)
08.09.25		EQS-News: GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences (EQS Group)
03.09.25		EQS-News: GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference (EQS Group)
20.08.25		EQS-News: GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs (EQS Group)
18.08.25		EQS-News: GeoVax to Present at the Emerging Growth Conference on August 20, 2025 (EQS Group)
30.07.25		EQS-News: GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains (EQS Group)
28.07.25		EQS-News: GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology (EQS Group)
24.07.25		EQS-News: GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results (EQS Group)
22.07.25		EQS-News: GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025 (EQS Group)
16.07.25		EQS-News: GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand (EQS Group)
14.07.25		EQS-News: GeoVax to Present at the Emerging Growth Conference on July 16, 2025 (EQS Group)
03.07.25		EQS-News: GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat (EQS Group)
03.07.25		EQS-News: GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat (EQS Group)
02.07.25		EQS-News: GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives (EQS Group)
01.07.25		EQS-News: GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering (EQS Group)
25.06.25		EQS-News: GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection (EQS Group)
24.06.25		EQS-News: GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy (EQS Group)
17.06.25		EQS-News: GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting (EQS Group)
12.06.25		EQS-News: GeoVax to Participate in BIO International Convention 2025 (EQS Group)
11.06.25		EQS-News: GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency (EQS Group)
10.06.25		EQS-News: GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients (EQS Group)
09.06.25		EQS-News: GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia (EQS Group)
04.06.25		EQS-News: GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology (EQS Group)
27.05.25		EQS-News: GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance (EQS Group)
08.05.25		EQS-News: GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 (EQS Group)
24.04.25		EQS-News: GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress (EQS Group)
23.04.25		EQS-News: GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 (EQS Group)
22.04.25		EQS-News: GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations (EQS Group)
16.04.25		EQS-News: GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum (EQS Group)
15.04.25		EQS-News: GeoVax to Present at the Emerging Growth Conference on April 16, 2025 (EQS Group)
15.04.25		EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events (EQS Group)
09.04.25		EQS-News: GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent (EQS Group)
27.03.25		EQS-News: GeoVax Reports 2024 Year-End Financial Results and Provides Business Update (EQS Group)
24.03.25		EQS-News: GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (EQS Group)
12.03.25		EQS-News: GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK (EQS Group)
11.03.25		EQS-News: GeoVax to Present at the 37th Annual Roth Conference (EQS Group)
04.03.25		EQS-News: Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025 (EQS Group)
03.03.25		EQS-News: GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy (EQS Group)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Nach Allzeithoch: Rally geht nicht weiter - Goldpreis fällt deutlich

Beyond Meat-Aktie mit extremen Kursschwankungen - was steckt dahinter?

Wegen Warrant-Einlösung: D-Wave Quantum-Aktie fällt - Quantum eMotion Blick

TeamViewer-Aktie bricht ein: Unternehmen zeigt sich bei Umsatzprognose für 2025/2026 skeptisch

Goldpreis trotzt dem Abverkauf: Neue Stabilität in Sicht?

ATX schließt im Plus -- DAX schlussendlich mit Verlusten -- US-Märkte gaben nach -- Asiens Börsen letztlich im Minus

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.10.2025 16:23
Kaufwert:	EUR
	Hinzufügen Speichern

Geovax Labs Aktie

WKN DE: A1CWWR / ISIN: US3736782000

Nachrichten zu Geovax Labs Inc

Newssuche

Meistgelesene Nachrichten